Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn’s Disease in Clinical Remission

Digestive Diseases and Sciences

Volumn 60, Issue 8, 2015, Pages 2427-2435

  Raftery, Tara ^a   Merrick, Megan ^a   Healy, Martin ^b   Mahmud, Nasir ^a   O’Morain, Colm ^c   Smith, Sinead ^c   McNamara, Deirdre ^c   O’Sullivan, Maria ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Calprotectin; Crohn s disease; Inflammatory bowel disease; Intestinal inflammation; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; TUMOR NECROSIS FACTOR INHIBITOR; VITAMIN D; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CORRELATION ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RISK FACTOR; STEROID THERAPY; SUMMER; UNDERWEIGHT; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WINTER; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; VITAMIN D DEFICIENCY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COMORBIDITY; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84937519455     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3620-1     Document Type: Article

References (37)

1. Suibhne TN, Cox G, Healy M, O’Morain C, O’Sullivan M. Vitamin D deficiency in Crohn’s disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis. 2012;6:182–188.
2. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
3. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.
4. Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–383.
5. Ham M, Longhi MS, Lahiff C, Cheifetz A, Robson S, Moss AC. Vitamin d levels in adults with Crohn’s disease are responsive to disease activity and treatment. Inflamm Bowel Dis. 2014;20:856–860.
6. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology. 2012;142:482–489.
7. Garg M, Rosella O, Lubel JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2634–2643.
8. Jørgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF. Active Crohn’s disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407–e413.
9. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.
10. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed Web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20:2276–2285.
11. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.
12. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930.
14. Laird E, McNulty H, Ward M, et al. Vitamin D deficiency is associated with inflammation in older Irish adults. J Clin Endocrinol Metab. 2014;99:1807–1815.
15. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.
16. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
17. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
18. Ananthakrishnan AN, Cheng SC, Cai T, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:821–827.
19. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35:308–316.
20. Joseph AJ, George B, Pulimood AB, Seshadri MS, Chacko A. 25 (OH) vitamin D level in Crohn’s disease: association with sun exposure & disease activity. Indian J Med Res. 2009;130:133–137.
21. Kelly P, Suibhne TN, O’Morain C, O’Sullivan M. Vitamin D status and cytokine levels in patients with Crohn’s disease. Int J Vitam Nutr Res. 2011;81:205–210.
22. Elliott PR, Lennard-Jones JE, Hathway N. Simple index of Crohn’s disease activity. Lancet. 1980;1:876.
23. Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–1229.
24. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.
25. Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn’s patients. Clin Transl Gastroenterol. 2013;4:e33.
26. Raftery T, Martineau A, Greiller C, et al. Does vitamin D supplementation impact plasma cathelicidin, human beta defensin 2 and intestinal permeability in stable Crohn’s disease? Results from a randomised, double blind placebo controlled study. Proc Nutr Soc. 2013;72:E176.
27. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. 2008;13:6–20.
28. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017–1020.
29. Molander P, af Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011–2017.
30. Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn’s disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60:889–896.
31. de Bruyn JR, van Heeckeren R, Ponsioen CY, et al. Vitamin D deficiency in Crohn’s disease and healthy controls: a prospective case-control study in the Netherlands. J Crohns Colitis. 2014;8:1267–1273.
32. Driscoll RH, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology. 1982;83:1252–1258.
33. Hollander D, Truscott TC. Mechanism and site of small intestinal uptake of vitamin D3 in pharmacological concentrations. Am J Clin Nutr. 1976;29:970–975.
34. Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and intestinal resection. Am J Clin Nutr. 1991;54:548–552.
35. Emmen JM, Wielders JP, Boer AK, van den Ouweland JM, Vader HL. The new Roche vitamin D total assay: fit for its purpose? Clin Chem Lab Med. 2012;50:1969–1972.
36. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648–2652.
37. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007;8:5.